Irinotecan in the Management of Patients With Pancreatic Cancer
ByMark R. Green, MD,Melinda Harper, RN,Ahmad R. Safa, MD, PhD,Carol A. Sherman, MD,Chaudry M. Mushtaq, MD,Hamid Bahadori, MD,Frank J. Brescia, MD,Caio Max S. Rocha Lima, MD
Published: | Updated:
Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan ( Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with